NCT05535595

Precision Treatment With Angiotensin Converting Enzyme Inhibitor

Precision Treatment Based on Genetic Information Associated With Response to Angiotensin Converting Enzyme Inhibitor

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 77 (actual)
• Sponsor: Yonsei University · Academic / Other
• Sex: All
• Age: 20 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

Angiotensin converting enzyme inhibitors (ACEI) are the first-line treatment for high blood pressure and congestive heart failure, and have excellent effects in improving the prognosis of cardiovascular diseases. However, ACEI is frequently discontinued due to its adverse reaction. The adverse reaction to ACEI is not uncommon, especially in Asians. Discontinuation of ACEI is known to increase the risk of poor prognosis of cardiovascular diseases. Biomarkers for predicting adverse reaction to ACEI have not yet been developed. Recently, genes related to adverse reaction to ACEI have been identified. This study is a randomized prospective study, in which the experimental group decides whether to administer the drug based on genetic information, and the control group decides whether to administer the drug without the information. In the experimental group, participants who are predicted to have a high risk of adverse reation to ACEI will receive angiotensin receptor blockers (ARB), and those who are predicted to have a low risk of adverse reaction will receive ACEI. Control group will receive ACEI. The frequency of adverse reaction will be investigated between control and experimental groups. In the genotyping and control groups, at least 45 and 31 will be enrolled, respectively, and after drug administration, a phone follow-up will be conducted at 3 weeks, followed by a visit at the 6th week, and the study will be terminated.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	genotyping and selection of renin-angiotensin system blocker	One of perindopril or candesartan was chosen based on genotyping results on two NELL1 variants. * perindopril 4 mg/d after genotyping * candesartan 8 mg/d after genotyping
DRUG	Perindopril	perindopril 4 mg/d without genotyping

Timeline

• Start date: 2019-11-06
• Primary completion: 2021-08-02
• Completion: 2021-08-02
• First posted: 2022-09-10
• Last updated: 2023-01-11

Locations

1 site across 1 country: South Korea